Skip to main content
OpenTrials
Completed

NCT Number: NCT00733421

The Effect of Anti-inflammatory Analgesics on Pain Following Hallux Valgus Surgery

The effects of none-steroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase inhibitors (Coxibs) on the formation of bone and fracture healing have been a matter of debate since long.

There is, however, limited data in humans and further prospective randomised studies are warranted. Ekman et al studied in a prospective randomised double blind study the effects of celecoxib, a selective cox-II-inhibitor, on pain and bone healing following spine surgery. They found significant effects on reduction of pain and need for opioid analgesics postoperatively but could see no negative effects the numbers of "none-unions" at a 1-year follow up 3.

In a similar prospective randomised double-blind study design significant effects in reduction of pain and need for rescue analgesia was seen from the use of celecoxib in the perioperative multi-modal pain strategy for cruciate-ligament reconstruction and no negative effects could bee seen on six month follow-up of the strength of the reconstructed ligament.

The aim of the present study is to further study the effects of the perioperative use of etoricoxib, a selective cox-II-inhibitor (Coxibs), in a prospective randomised double-blind study on bone healing, pain and need for rescue analgesia in patients undergoing elective Hallux Valgus surgery with a standardised surgical technique including an osteotomy of metatarsale I and excision of exostosis.

Study population 100 American Society of Anesthesiology (ASA) physiological status1-2 patients scheduled for elective hallux valgus (HV) surgery

The patients are going to be randomised into 2 groups, 50 patients in each;

1. etoricoxib 90 mg once daily x 5 2. tramadol 100 mg twice daily x 5

First line rescue medication t. paracetamol 1 gr up to 4 gram daily Second line rescue t. oxycodone 10 mg

Primary study variables:

* X-ray evaluation (computer tomography (CT)-investigation) of bone healing assessed a CT-scan modelling of the osteotomy at twelve weeks after surgery * Number of patients requiring rescue medication * Patient assessment using "brief pain inventory" 24 hours and 2 weeks after surgery

Secondary study variables are;

* Visual Analogue Scale (VAS) grading Day 1-7 * Compliance to base medication * Need for rescue analgesia Day 1-7 * Adverse Effects

* Experience of any emetic symptoms * Experience of any gastrointestinal symptoms * Satisfaction with pain medication Day 20 * Wound dressing Day 20 * Clinical evaluation 17 weeks, final assessment

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

Foot & Ancle Surgical Center

Stockholm, 11542, Sweden

About this study

See brief summary

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Health ASA 1-2 patients 18-65 years of age

Exclusion criteria

  • ASA/NSAID allergy
  • Renal disease
  • Lithium therapy
  • Complicated cardiovascular disease

Treatment and study plan

Etoricoxib

Drug

90 mg once daily

Other names: Arcoxia

Tramadol

Drug

100 mg twice daily

Other names: Tiparol

Primary outcomes

  1. Number of Patients Requiring Rescue Medication

    Time frame: 7 day study period

    Number of patients requiring any further pain medication

Secondary outcomes

  1. Summary of Pain Scores, Day 1-7 of Visual Analogue Scale Grading of Pain

    Time frame: The first 7 days after surgery, during study pain medication

    VAS score 1-10 1=no pain 10 = worst possible pain, summary variable day 1-7; 7 - 70

  2. Compliance to Base Medication

    Time frame: 7-day study period, during study medication

    Number of patients that did not discontinue study medication before day 7

  3. Gastro-intestinal Symptoms

    Time frame: during the 7- day pain medication period

    Number of patients reporting any gastro-intestinal side effects; nausea and or vomiting, gastritis etc. assessed by patient and documented in written questionnaire

  4. Dizziness/Sleepiness

    Time frame: During the 7-day pain medication period

    Number of patients that experienced dizziness/sleepiness/fatigue, assessed by patient and documented in written questionnaire

  5. Wound Healing

    Time frame: 16 week follow-up

    healing process assessed by a blinded physician during the final outpatient clinic visit assessment graded; Good/neutral/bad

  6. Satisfaction With Pain Medication

    Time frame: during the first 20 days after surgery, 1st outpatient clinic visit

    satisfied or unsatisfied with study medication, assessed by patient in questionnaire

  7. Patient Assessed Overall Satisfaction With Surgery/Outcome

    Time frame: 16 weeks

    overall satisfaction with outcome, patients assessed satisfaction with the surgical procedure; satisfied, neutral or unsatisfied, written questionnaire.

  8. Patient Assessed Quality of Life

    Time frame: At 16-week post surgery follow-up

    Quality of Life evaluated by grading on a Visual Analogue Scale in the written questionnaireisual analogue scale grading 0-100; 0 death and 100 perfect quality of life

Sponsors and collaborators

Lead sponsor

Karolinska Institutet

Other

Registry information

Official study title

The Effect of Anti-inflammatory Analgesics on Bone Repair, Pain and Gastro-intestinal Side Effects After Hallux Valgus Surgery; a Prospective Randomised Double-blind Placebo Controlled Study.

Important dates

Study start
2008
Primary completion
2009
Study completion
2009
First posted
Aug 13, 2008
Registry last updated
Jan 20, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.